Heterogeneity of programmed cell death-ligand 1 expression in lung cancer  by Mansfield, Aaron et al.
February 2016 Abstracts S31sequenced the miRNA in these cells and found that cells
with EMT memory have distinct miRNA proﬁle
compared to cells with transient EMT, suggesting that
the epigenetic switch upon chronic IL-1b exposure leads
to selective gene expression. These ﬁndings, for the ﬁrst
time, demonstrate a unique feature in chronic inﬂam-
mation that allows cells to metastasize and eventually
grow in distant organs, suggesting that these cells may
serve as a reservoir for tumor metastasis and relapse.
The intent of this study is to ultimately identify targets to
intervene in preventing and treating metastatic behavior
in lung cancer.
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Background: The randomized, double-blind, placebo-
Controlled Study of Lanreotide Antiproliferative
Response in Neuroendocrine Tumors (CLARINET)
showed that treatment with the somatostatin analog
(SSA) lanreotide depot was associated with signiﬁcantly
prolonged progression-free survival (PFS) vs placebo
(PBO) in gastroenteropancreatic neuroendocrine tumors
(GEP-NETs), leading to FDA approval. Like GEP-NETs,
lung NETs express somatostatin receptors.
Methods: This multi-institutional study will enroll an
anticipated216patientswith lowgrademetastatic and/or
un-resectable NETs that have positive somatostatin scin-
tigraphy and who are treatment naïve or have had no
more than 1 course of systemic chemotherapy (cytotoxic,
molecular targeted therapy or interferon). Patients will be
randomized 2:1 to receive lanreotide depot 120 mg via
deep subcutaneous injection plus best standard of care or
PBO. An estimated 175PFS events (disease progression or
death) on both arms will provide a 90% power to detect a
statistically signiﬁcant treatment effect using a two-sided
log rank test at a signiﬁcance level of a¼0.05.
Results: Anticipated results include the primary
endpoint of PFS in both arms, as well as secondaryendpoints which include objective radiologic response
rate, overall survival, effects on plasma chromogranin A,
and safety/tolerability.
Conclusion: Therapeutic agents for the treatment of
lung NETs are currently limited. This study will provide
data on the efﬁcacy of lanreotide depot for patients with
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Introduction: The expression of programmed cell death
ligand 1 (PD-L1) provides limited predictive value in
identifying patients most likely to respond to immuno-
therapy. Since the heterogeneity of PD-L1 expression
may lead to sampling error and the misclassiﬁcation of
PD-L1 status, we assessed the heterogeneity of PD-L1
expression in paired resected multifocal lung cancers
with the hypothesis that expression is heterogeneous.
Methods: PD-L1 was assessed by immunohistochem-
istry (CellSignaling #13684 clone E1L3N). Five percent
or greater membranous expression was considered
positive. A chromosomal rearrangement-based next-
generation sequencing approach was used to deﬁne
paired lesions as independent primaries or related le-
sions. Descriptive and agreement statistics were used for
analysis.
Results: A total of 67 multifocal lung cancers from 32
patients were sequenced and stained for PD-L1. There
was agreement of PD-L1 expression by the tumor cells in
paired lesions of 20 patients, and disagreement of PD-L1
expression by the tumor cells in paired lesions of 12
patients (kappa¼0.01). Sequencing identiﬁed that 23
patients had independent primary lung cancers and that
nine patients had related cancers. Amongst the patients
with independent cancers, there was agreement of
PD-L1 expression by the tumor cells in paired lesions of
12 patients, and disagreement of PD-L1 expression by
the tumor cells in paired lesions of 11 patients
(kappa¼0.31). Amongst the patients with related lung
cancers, there was agreement of PD-L1 expression by the
tumor cells in paired lesions of 8 patients, and
disagreement of PD-L1 expression by the tumor cells in
paired lesions of 1 patient (kappa¼0.73).
Conclusion: Overall, the expression of PD-L1 is hetero-
geneous amongst paired multifocal lung cancers, but
S32 Journal of Thoracic Oncology Vol. 11 No. 2Sthere are high levels of agreement amongst related
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Mao Mao WuXi AppTec, Shanghai, ChinaTracking tumor-associated mutation in plasma can serve
as biomarkers to facilitate cancer diagnosis and provide
guidance for target therapy. The intrinsic low abundance
and short fragments of circulating cell-free tumor DNA
(cfDNA) make the mutation detection from plasma a
challenging task. Next Generation Sequencing (NGS) al-
lows high throughput mutation analysis of cancer genes
by massively parallel sequencing. Ion Ampliseq panel is
able to construct the library with as little as 10ng DNA,
suitable for the limited amount from cfDNA. However,
the commercial Ampliseq panel together with the TVC
(Ion Torrent variant caller software) analysis was mainly
designed for mutation detection from FFPE samples. The
sensitivity is not good enough for cfDNA mutation
detection based on our assessment.
Here we have established a strategy to detect so-
matic mutations of colon and lung cancer with plasma
based on AmpliSeq Ion Torrent System. Firstly, a colon
and lung panel was designed for small amplicons (less
than 140bp), so as to better capture small cfDNA
fragments as effective templates in multiplex PCR. The
ampliﬁcation test shows that our panel produced
amplicons with a good uniformity when applied to
cfDNA. Secondly, background noise analysis has shown
the noise unevenly distributed along the genome and
error hotspots repeatedly showed up among different
samples. Based on the features of background noise, we
have developed a new algorithm to distinguish low
level mutations from sequencing errors, which makes
use of sequencing data from healthy individuals as
reference to estimate the sequencing error proﬁle. A
reliability of the mutant allele at each position was
evaluated by statistical test of background noise versus
signal. To evaluate the detection limit of our approach,
a cell line mix which contains several mutations at
different level of mutations was examined. Digital
droplet PCR (ddPCR) assay was used to conﬁrm the
allele frequency of each mutation. This analysis dem-
onstrates that our approach is able to call mutations at
a fractional abundance of 0.15-0.3%, depending on the
genomic positions. The allele frequency from
sequencing result correlates well with ddPCR result(R2¼0.90). Moreover, the analytical speciﬁcity is higher
than 99% with such detection limit.
To test the clinical performance of our method, cfDNA
from non-small cell lung cancer (NSCLC) patients was
used. With 10ng cfDNA, this method is able to call mu-
tation as low as 0.5%, the lowest clinical sample tested,
while with the commercial kit and variant analysis
software, it only calls at 5%. The detection limit of our
approach for clinical cfDNA sample will be determined
with more tests.
Ion Torrent PGM has been widely used in clinical
environment, because of its cost and time effective way
compatible with clinical practice. In this proof-of-concept
study, our strategy comprised of an optimized panel
suitable for cfDNA and a novel variant calling algorithm
signiﬁcantly improves the detection limit of the PGM
platform, making it possible to detect low abundant
mutations from plasma. We envision this approach could
have utility for patient stratiﬁcation, monitoring
response to therapies and detection of relapse.Constitution of ALK fusion variants in
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Introduction: The purpose of the study is to investigate
the constitution of anaplastic lymphoma kinase (ALK)
fusion variants in East Asian lung adenocarcinoma
(LUAC) patients and to provide instructional data for the
variants that should be included in the companion
diagnostic assay to screen for ALK positive patients.
Methods: From June 2014 to August 2015, 158 ALK
fusion positive formalin-ﬁxed, parafﬁn-embedded
(FFPE) samples were identiﬁed, including 3 patient-
derived xenograft (PDX) tissues and 155 resected or ﬁne
needle aspiration (FNA) tissues, all derived from Korean
or Chinese patients. Either puriﬁed RNA or crude tissue
lysate from the 158 FFPE samples were analyzed by
NanoString nCounter Elements assay with a multiplexed
probe mix in a single tube targeting ALK fusion tran-
scripts including 29 known variants.
Results: Of the total 158 ALK fusion positive samples,
133 samples harbored echinoderm microtubule-
associated protein-like 4 ALK (EML4-ALK) fusion, 4 samples
